BioAge Labs Reports Q2 2025 Financial Results and Progress

BioAge Labs, Inc. ( (BIOA) ) has released its Q2 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.

BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company is known for its innovative approach to addressing metabolic aging through its proprietary discovery platform built on human longevity data.

In its second quarter of 2025, BioAge Labs reported significant progress in its clinical pipeline and discovery platform. The company completed IND-enabling studies for its lead product candidate, BGE-102, an oral NLRP3 inhibitor aimed at treating obesity, and is on track to initiate Phase 1 trials later this year. Additionally, BioAge expanded its APJ agonist pipeline through a strategic option agreement and advanced its discovery platform by profiling over 17,000 samples from the HUNT Biobank.

Key financial metrics from the second quarter include a notable increase in research and development expenses, which rose to $19.8 million from $10.5 million in the same period last year, primarily due to increased costs related to the APJ agonist programs and BGE-102. General and administrative expenses also saw an increase, reaching $7.3 million. The company reported a net loss of $21.6 million, compared to $13.6 million in the previous year, but maintains a strong cash position with $313.4 million in cash, cash equivalents, and marketable securities.

BioAge’s strategic partnerships with major pharmaceutical companies like Novartis and Lilly ExploR&D continue to advance, focusing on discovering novel therapeutic targets and developing therapeutic antibodies for metabolic aging. These collaborations, along with the company’s robust financial position, support its ongoing efforts in developing transformative therapies for metabolic diseases.

Looking forward, BioAge Labs remains committed to advancing its clinical programs and leveraging its discovery platform to develop new therapies targeting metabolic aging. The company’s management is optimistic about its future prospects, with sufficient resources to fund operations through 2029, as it continues to pursue its mission of addressing metabolic diseases through innovative scientific approaches.